|
 |
FDA Approval Activities for this Drug…
Vaniqa (eflornithine hydrochlorine) Cream,13.9%, Bristol-Myers Squibb NDA 21-145 7/27/00 8/3/00 8/3/00 7/8/03 Vaniqa Indications: For the reduction of unwanted facial hair in women. EFLORNITHINE HYDROCHLORIDE Cream; Topical 13.9% VANIQA WOMEN FIRST
For the most up-to-date approval information, please locate this API using the drug index. |
|
|